Royalty Report: Drugs, Proteins, Antibody – Collection: 293999

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Drugs
  • Proteins
  • Antibody
  • Drug Discovery
  • Agriculture Forestry & Fishing
  • Biotechnology
  • Crop Production
  • Vaccine
  • Cell Line

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 293999

License Grant
Israel Licensor hereby grants Israel Licensee, and Licensee hereby accepts from Licensor, an exclusive world-wide license under the Platform IP, the Protein IP and the Other IP owned by or licensed to Licensor (collectively, the “Licensed Information”) to research, develop, make, have made, register, import, manufacture, use, sell, offer for sale, produce, sublicense, commercialize, distribute the Proteins and/or pharmaceutical products embodying, based on or using the Proteins (the Licensed Products) for all indications (the “License”) and for no other purposes whatsoever.

Licensor agrees to grant Licensee a right of first look at Licensor’s proprietary product(s) for the treatment of Gauchers Disease, to enable Licensee to evaluate its interest in negotiating and obtaining the GCD License (as such term is defined herein), all subject to and in accordance with the terms and conditions set out herein.

The Parties hereby agree to collaborate in the development, and the manufacturing of the Proteins, on the basis of the Platform IP.

License Property
Licensed Product(s) shall mean the products based on or using the Proteins to research, develop, make, have made, register, import, manufacture, use, sell, offer for sale, produce, sublicense, commercialize, distribute the Proteins and/or pharmaceutical products.

Protein(s) each of the two (2) therapeutic proteins as selected by Licensee and agreed upon by Licensor (such agreement not to be unreasonably withheld, conditioned or delayed), expressed in plant cell-expression system outlined in this agreement as might be substituted subject to the terms of this Agreement.

Platform IP shall mean Licensor’s existing and future proprietary recombinant plant culture process and technologies directly related to such process, and improvements thereto, as may be further developed in the course of the collaboration, or otherwise, by or for Licensor, at any time prior to the expiration of fifteen (15) years following the First Commercial Sale of the first Licensed Product. The list of patents and patent applications included under the Platform IP hereto as the Platform Patents.
6,391,638 – Cell/tissue culturing device and method

IP shall mean (i) all inventions, materials, compounds, compositions, substances, methods, processes, techniques, know-how, technology, data, information, discoveries and other results of whatsoever nature, and any patents, copyrights, proprietary intellectual or industrial rights directly or indirectly deriving therefrom, as well as provisionals, patent applications (whether pending or not), and patent disclosures together with all reissuances, continuations, continuations in part, revisions, extensions, and reexaminations thereof; (ii) all trademarks, service marks, copyrights, designs, trade styles, logos, trade dress, and corporate names, including all goodwill associated therewith; (iii) any work of authorship, regardless of copyrightability, all compilations, all copyrights; and (iv) all trade secrets, confidential information and proprietary processes.

Field of Use
The collaboration and licensing agreement is for the development and manufacturing of two proteins, using its plant cell system.

Plant cell expression system is capable of producing “human like” proteins that maintain the amino acid structure of the desired human protein as well as a very similar, but not identical, glycan, or sugar, structure.

In the biotechnology field, the production or manufacture of recombinant proteins is commonly referred to as the “expression” of such proteins. Recombinant therapeutic proteins are proteins that are produced by different genetically modified organisms following the insertion of the relevant DNA into their genome and are the basis of most biopharmaceutical drugs currently under development.

IPSCIO Record ID: 274941

License Grant
The following is granted by Icon to Licensee pursuant to the Option Agreement.

A non-exclusive worldwide license under the Patents to develop, test, use and commercialize German Licensor’s Technology in the Israel Licensee Field and to make and have made Proteins expressed by using Licensor’s Technology in the Licensee Field; and

An exclusive worldwide license under the Patents to develop, test, use and commercialize Licensor’s Technology to make and have made Research Proteins in the Licensee Field for the following Protein products human growth hormone and human follicle stimulating hormone. For the avoidance of doubt, the license in respect to any lgG Protein shall be non-exclusive, pursuant to the Section above.

License Property
Protein shall mean any protein, protein fragment, peptide or polypeptide regardless of formation or structure.

Patents International
Suggested use of Patents to provide freedom to operate
Glucocerebrosidase
Follicle stimulating hormone (FSH)
Human Growth Hormone (hGH)
A proprietary humanized full lgG antibody

Licensed Product(s) shall mean any pharmaceutical Research Protein and each additional pharmaceutical Protein expressed by Licensee or its Affiliates or sub-licensees using Licensor’s Technology. For the avoidance of doubt, active ingredients for drugs developed by Licensee with the use of Licensor’s Technology and sold as such, shall be deemed as Licensed Product(s).

Licensor’s Technology shall means a proprietary platform technology known as “Transgene Operating Systems”.

Research Proteins
Human Glucocerebrosidase
Human Follicle Stimulating Hormone (hFSH)
Human Growth Hormone (hGH)
A proprietary humanized full lgG antibody

Research Program directed towards expressing the cDNA encoding of the 4 (four) proteins listed hereto in plant cells grown in Licensee’s bio-reactor systems with the use of Licensor’s Technology is currently underway.

Immunoglobulin G (IgG) is a type of antibody. Representing approximately 75% of serum antibodies in humans, IgG is the most common type of antibody found in blood circulation.

Field of Use
This agreement pertains to the drug industry relating to the Licensee Field that shall have the meaning to the research, development, production and commercialization of pharmaceutical proteins and the expression thereof in plant cell culture systems.

IPSCIO Record ID: 56588

License Grant
In this related party agreement, the Licensor hereby grants to Licensee a nonexclusive license in the Territory, with the right to sublicense, to use iBioLaunchâ„¢ Technology and iBio Additional Technology to conduct Process Development, Scale-Up, and R&D activities on Pharmaceutical Products in the Territory. Additionally, subject to the terms and conditions of this Agreement, Licensor hereby grants to Licensee a nonexclusive license in the Territory, with the right to sublicense, to use the iBio Additional Technology to conduct Process Development, Scale-Up, and R&D activities on Products in the Territory.
License Property
The patents and technology are for the accelerated discovery and production of improved vaccines, monoclonal antibodies, therapeutic proteins, and other products derived from green plants utilizing its iBioLaunchâ„¢ plant-based platform technology and other proprietary technologies.

7,012,172   VIRUS INDUCED GENE SILENCING IN PLANTS   3/14/2006
          
7,491,509   SYSTEM FOR EXPRESSION OF GENES IN PLANTS   2/17/2009
          
7,683,238   PRODUCTION OF PHARMACEUTICALLY ACTIVE PROTEINS IN SPROUTED SEEDLINGS   3/23/2010
          
7,692,063   PRODUCTION OF FOREIGN NUCLEIC ACIDS AND POLYPEPTIDES IN SPROUT SYSTEMS   4/6/2010
          
8,058,511   SYSTEM FOR EXPRESSION OF GENES IN PLANTS   11/15/2011
          
8,148,608   SYSTEMS AND METHODS FOR CLONAL EXPRESSION IN PLANTS   4/3/2012
          
8,173,408   RECOMBINANT CARRIER MOLECULE FOR EXPRESSION, DELIVERY AND PURIFICATION OF TARGET POLYPEPTIDES   5/8/2012
          
8,591,909   RECOMBINANT CARRIER MOLECULE FOR EXPRESSION, DELIVERY AND PURIFICATION OF TARGET POLYPEPTIDES   11/26/2013
          
8,597,942   SYSTEM FOR EXPRESSION OF GENES IN PLANTS   12/3/2013
          
8,951,791   SYSTEM FOR EXPRESSION OF GENES IN PLANTS   2/10/2015
          
9,012,199   RECOMBINANT CARRIER MOLECULE FOR EXPRESSION, DELIVERY AND PURIFICATION OF TARGET POLYPEPTIDES   4/21/2015

Field of Use
This agreement pertains to the patents and technologies for research, process development and scale-up, and manufacturing of plant-derived products in a manufacturing facility designed for that purpose relating to drugs in the healthcare industry.

IPSCIO Record ID: 294274

License Grant
The parties collaborated to develop a long-acting Factor VII compound and amended the Original Agreement to incorporate all of the Amendments into one document.

Licensor hereby grants, and agrees to grant, to Swiss Licensee an exclusive (even as to Licensor), royalty-bearing license under the Licensor Intellectual Property in the Field of Use during the Term, (i) to conduct research, sample, develop (including clinical development), manufacture, make, use, market, promote, sell, offer for sale, have sold, distribute, import and export New Products in the Territory, and (ii) to use the Reagents in the Territory solely for the purpose of making New Products. Such license does not permit Licensee (x) to practice or use the Licensor Intellectual Property outside the Field of Use or (y) to sublicense any of its rights without the prior written approval of Licensor.

Licensor hereby grants, and agrees to grant, to Licensee a worldwide, exclusive (even as to Licensor), perpetual, irrevocable, and royalty-bearing (subject only to the payment of royalties in accordance with this agreement) license, with the right to sublicense, to any Carved Factor VII Claims that do not constitute Licensee Improvements for any and all purposes. In addition to the foregoing, Licensor hereby grants, and agrees to grant, to Licensee a worldwide, exclusive (even as to Licensor), perpetual, irrevocable, and royalty-free license, with the right to sublicense, to any Carved Factor VII Claims that constitute Licensee Improvements for any and all purposes.

License Property
New Product shall mean the following (a) any of the Licensee Materials modified using either (i) the Licensor Technology, (ii) any Licensor Improvements, or (iii) any combination of all or some of (i) and (ii) above, and (b) any Licensee Materials covered by any Carved Factor VII Claims (except to the extent such claims constitute Licensee Improvements) .

Potential Carved Factor VII Claims shall mean any composition-of-matter claims and any method of treatment claims that are supported by Patent Rights Controlled by Licensor that (i) do or could explicitly and solely recite and claim Licensee Materials, or (ii) any Licensee Improvements made or reduced to practice by Licensor.

Licensor Technology means the Licensor Patents and any Know-How Controlled by Licensor relating to methods and processes for the glycosylation design and remodeling of proteins, peptides and antibodies, including, without limitation, its GlycoAdvance®, GlycoPEGylation™ and GlycoConjugation™ technologies, and other carbohydrate dynthesis processes, and all Know-How resulting from work conducted by Licensor during the Term.

Licensor Patents means (a) all Patent Rights relating to methods and processes for glycosylation design and remodeling of proteins, peptides and antibodies that are Controlled by Licensor, including, but not limited to (i) the Patent Rights listed, (ii) the Patent Rights developed by Licensor in the conduct of the Work Plan during the Term of this Agreement, and (iii) any later acquired Patent Rights Controlled by Licensor and used to develop any New Product, and (b) all Patent Rights Controlled by Licensor that would be infringed by the research, development (including clinical development), manufacture, making, use, marketing, promotion, sale, offer for sale, distribution, import and export of New Products in the Territory.
US Patent #6,800,468 – UDP-galactose .beta.-N-acetyl-glucosamine .beta.1,3galactosyltransferases, .beta.3Gal-T5
US Patent #6,995,004 – UDP-N-ACETYLGLUCOSAMINE GALACTOSE-.beta. 1,3-N-ACETYLGALACTOSAMINE-.alpha.-R / N-ACETYLGLUCOSAMINE-.beta. 1,3,-N-ACETYLGALACTOSAMINE-.alpha.-R (GLCNAC TO GALNAC) .beta.1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE, C2/4GNT
US Patent #6,635,461 – UDP-N-acetylglucosamine galactose-.beta.1, 3-N-acetylgalactosamine-.alpha.-R/(GlcNAc to GalNAc) .beta.1,6-N-acetylglucosaminyltransferase, C2GnT3

Licensor Improvements means any and all Improvements relating to the Licensor Technology made, conceived, or reduced to practice by (i) either Licensor or Licensee or both in the conduct of the Work Plan under this Agreement, (ii) either Licensor or Licensee or both under this Agreement, (iii) Licensee in the practice of any Licensor Technology under the licenses granted to Licensee in this agreement, or (iv) Licensee in the conduct of any activity using any Ownership Rights assigned to Licensee pursuant to this Agreement, in each case of (i), (ii), (iii) or (iv), other than the Licensee Materials, the Licensee Materials modified using the Licensor Technology and New Product. Specifically excluded from Licensor Improvements are (1) formulations, combinations and methods of treatment to the extent relating to Licensee Materials, the Licensee Materials modified using the Licensor Technology and New Products and (2) analytical techniques and purification methods invented, developed or reduced to practice solely by Licensee that did not originate from or are not derived from Licensor (collectively, the Techniques).

Licensor Intellectual Property means Licensor Technology and the Licensor Improvements.

Patent Rights shall mean individually and collectively any and all patents and/or patent applications and provisional applications, all inventions disclosed therein, and any and all continuations, continuations-in-part, continued prosecution applications, divisions, renewals, patents of addition, reissues, confirmations, registrations, revalidations, revisions and re-examinations thereof, utility models, petty patents, design registrations and any and all patents issuing therefrom and any and all foreign counterparts thereof and extensions of any of the foregoing including without limitation extensions under the U.S. Patent Term Restoration Act, extensions under the Japanese Patent Law, and Supplementary Protection Certificates (SPCs) according to Counsel Regulation (EEC) No. 1768/92 and similar extensions for other patents under any applicable law in any country of the world. Licensee hereby grants to Licensor, for the term of the Work Plan, a non-exclusive, royalty free, license under the Licensee Technology to use such Licensee Technology for the sole purpose of carrying out its obligations under the Work Plan. Licensee shall retain at all times all of its rights, title and interest to the Licensee Technology.

Licensor Exclusive Compounds shall mean any and all forms of erythropoietin and granulocyte colony stimulating factor including, but not limited to, with respect to either of the foregoing full length proteins, truncated proteins, fusion proteins, analogs, mutants, splice variants, and conjugates with other molecular entities such as proteins, peptides, organic or inorganic substances.

Field of Use
Licensor's technology is to develop and commercialize next-generation versions of Factors VIIa, VIII and IX.

Factor VIIa is used in the treatment of bleeding episodes and for the prevention of bleeding during surgery or invasive procedures in patients with congenital hemophilia with inhibitors to coagulation factors VIII or IX.

IPSCIO Record ID: 315803

License Grant
Licensee hereby grants to Licensor a non-exclusive, royalty bearing license, under Licensee Program Know-How Patent Rights, Licensee Contributed Know-How Patent Rights, Licensee Program Methodology Patent Rights, Licensee Program Know-How, Licensee Contributed Know-How and Licensee Program Methodology, to use Licensor Accessible Program Clones and Proteins encoded therein in order to discover, research, develop, make, import, use, offer to sell and sell Licensor Small Molecule Drugs in the Territory; such license shall include the right to grant sublicenses.
License Property
Program Clone means a clone (including the DNA sequence information, whether partial or full-length, pertaining to the clone), identified in the course of the Licensee Discovery Program or included in the Existing Tango Technology, Licensee Contributed Know-How or Licensor Contributed Know-How. Licensee Program Methodology Patent Right' means a Patent Right that relates to methods that are or were at any time included in Licensee Program Metholodogy.

Protein means a high molecular weight (i.e., weighing greater than 1000 daltons) polymer compound composed of a variety of amino acids joined by peptide linkages, including allelic variants thereof and post-translationally modified variants thereof (i.e., glycosylated Proteins). For purposes of this Agreement, Protein does not include an Antibody.

Small Molecule Drug means a therapeutic or prophylactic product, the active ingredient of which is a synthetic small molecule (including but not limited to a Peptido Mimetic), a natural product or a macromolecule that
(a) is identified in a screening assay on the basis of its interaction with a biological target that has been identified through use of a Program Clone, or (b) is designed or developed using medicinal chemistry, SAR or combinatorial
chemistry techniques to interact with a biological target that has been identified through use of a Program Clone, provided, however, that a Small Molecule Drug does not include any Therapeutic Product or any therapeutic and/or prophylactic product in which the active ingredient is a Protein, an Antibody, an Antisense Drug or a Gene Therapy Drug.

Gene Therapy Drug means any drug or drug candidate, excluding an Antisense Drug, which consists of nucleic acid or a functional analog, derivative or homologue thereof and which, upon delivery by any means, provides a gene product encoded therein which is expressed.

Antisense Drug means any drug or drug candidate which consists of nucleic acid or a functional analog, derivative or homologue thereof and which is complementary to a segment of DNA of a target gene or such target genes cognate RNA and which, upon delivery by any means, alters the transcription, processing, elaboration, RNA expression or Protein production of or by such target gene.

Antibody means (a) a molecule comprising four (4) polypeptide chains (two (2) identical light chains and two (2) identical heavy chains) that are held together by disulfide bonds and form two (2) identical antigen binding sites or (b) any combination, fragment or altered form of a molecule(s) of the type described in (a) (e.g., single chain antibodies).

Licensor Small Molecule Drug means a Small Molecule Drug identified or designed by Licensor through the use of a Licensor Accessible Program Clone and/or the Protein encoded therein.

Existing Tango Technology means the cDNA libraries, genomic sub-libraries, signal peptide trap libraries (including the clones derived from such libraries and the Proteins encoded therein) and the Proteins and all associated data and information.

Therapeutic Product means a therapeutic and/or prophylactic product in which the active ingredient is a Program Protein or a Derivative thereof.

Peptido Mimetic means  synthetic organic molecule that (a) is designed or developed using medicinal, SAR or combinatorial chemistry techniques to incorporate key structural features of a Protein (the Mimicked Protein). Cb) if a peptide • has an amino acid sequence that is at least fifty percent (50%) different from that of the  Mimicked Protein, and (c) has a molecular weight that is less than twenty (20%) percent of that of the Mimicked Proteina,

Diagnostic Product means any diagnostic product, in the form of a device, compound, kit or service, with utility in the diagnosis, prognosis, prediction or disease management of a disorder that (a) is developed through the use of Licensee Program Know-How or, subject to any limitations on the use of such Know-How by Licensor, Licensee Contributed Know-How and/or is covered by a Valid Claim included in Licensee Program Know-How Patent Rights or, subject to any limitations on the use of such Patent Rights by Licensor, Licensee Contributed Know-How Patent Rights, (b) embodies, or operates through the detection of a Program Clone or a Program Protein (or a Derivative thereof), and (c) will complement the use of any therapeutic product under development or marketed by Licensor or a development or marketing partner of Licensor (a Licensor Corresponding Drug).

Licensee Program Methodology means any methods (including without limitation bioinformatics tools, processes, protocols, assays, automated and semi-automated techniques, molecular biology methods and other methods for the discovery, production and/or characterization of Proteins), that (a) are developed in the course of the Licensee Discovery Program, including any improvements in methods technology derived from, or based upon, any Licensor Contributed Know-How and/or Licensee Contributed Know-How and (b) are not properly in the public domain.

Licensee Discovery Program means the therapeutic Protein  discovery program to be undertaken by Licensee pursuant to this Agreement, with the goal of identifying and qualifying potential therapeutic Proteins for further pre-clinical development, clinical development, manufacturing and commercialization, as described in greater detail in the Program Plan.

Licensee Accessible Program Clone means (a) a Program Clone  that is not identified through the use of Licensor Contributed Know-How, or (b) a Program Clone that is identified through the use of Licensor Contributed Know-How and with respect to which either (i) Licensor has not placed any limitation on Licensees use of such Program Clone for the identification or design of Licensee Small  Molecule Drugs or (ii) Licensor has placed the limitation that Licensee shall not have the right to use such Program Clone for the identification or design of Licensee Small Molecule Drugs for a period of twelve (12) months from the date on which such Program Clone is identified and such twelve (12) month period has elapsed.

Licensor Accessible Program Clone means (a) a Program Clone that is not identified through the use of Licensee Contributed Know-How, or (b) a Program Clone that is identified through the use of Licensee Contributed Know-How and with respect to which either (i) Licensee has not placed any limitation on Licensors use of such Program Clone for the identification or design of Licensor Small Molecule Drugs or (ii) Licensee has placed the limitation that Licensor shall not have the right to use such Program Clone for the identification or design of Licensor Small Molecule Drugs for a period of twelve (12) months from the date on which such Program Clone is identified and such twelve (12) month period has elapsed.

Field of Use
The field of use is for the therapeutic and/or prophylactic application in human health care of Proteins or Derivatives thereof. The goal is to identify and qualify potential therapeutic proteins, small molecule targets and diagnostics for further development and commercialization.

IPSCIO Record ID: 240480

License Grant
The University grants to Licensee a world-wide, non-transferable license under its rights in and to the Patent Rights, only in the Field of Use, to make, have made, use, sell, offer to sell and import Patent Products, and to use and practice the Licensed Methods and Patent Rights, including for purposes of identifying, creating, discovering, developing and commercializing Identified Products, in the Field of Use.

The University also grants to Licensee the right to sublicense to third parties.

License Property
Therapeutic Licensed Product means a Licensed Product that is used to prevent, treat or cure one or more diseases and/or conditions of human beings or animals.

Diagnostic Licensed Product means a Licensed Product that is used as a human or veterinary diagnostic and/or prognostic.

Identified Product means a Product that has prophylactic, therapeutic, diagnostic or prognostic value and is identified, created, discovered or developed as a result of practicing the Licensed Method, use of Patent Products, or use or practicing of any Product, process or method anywhere in the world covered by a Valid Claim within the Patent Rights in any one country.

Certain inventions, generally characterized as Nucleic Acids Encoding Neural Axon Outgrowth Modulators, Netrins, Netrin Receptors, Semaphorin Receptors, Human Netrin~1, Promoters of Neural Regeneration and Compositions for Promoting Nerve Regeneration.

Patents include small molecule, Ligands and Receptors.

Field of Use
Field of Use means any and all uses, including for or relating to human or veterinary prophylaxes; therapeutics, diagnostics and prognostics, including without limitation use in assaying or screening for therapeutic, diagnostic and prognostic targets, validation of therapeutic, diagnostic and prognostic targets, and use for drug discovery purposes such as the identification of new chemical entities, but specifically excluding Research Reagent Use.

IPSCIO Record ID: 309678

License Grant
The Licensor hereby grants to the Japanese Licensee an exclusive (even as to Licensor (Licensor Retained Rights)) license under the Licensor Technology and Licensor’s interest in the Collaboration Technology (with the right to grant sublicenses (Licensee Sublicensing Rights)), solely to conduct any Project during the Research Term (the “Research License”). Licensor will disclose all Licensor Technology to Licensee immediately upon execution of this Agreement or from time to time upon request of Licensee.
License Property
Licensor Technology means Licensor Know-How and Licensor Patent Rights. Collaboration Technology means Collaboration Know-How and Collaboration Patent Rights.

Licensor has expertise and proprietary technical information and know-how relating to application of protein folding, trafficking and clearance-based, small molecule therapeutics for the treatment of diseases and is committed to the research and development of therapeutic methods and products for the treatment of diseases.

Licensed Product means any product for use in the Field that contains a Development Compound (or any pharmaceutically acceptable radioisomers, stereoisomers, racemates, solvates, salt forms, bases, anhydrides, hydrates, polymorphs, prodrugs, and ester forms thereof) as an Active Ingredient.

Development Compound means an Active Compound in a Hit Series or derived from a Hit Series that is designated by Licensee, in Licensee’s sole discretion, for further Development by Licensee’s exercise of its Development Option for that Active Compound in accordance with this agreement (Development Compounds). For avoidance of doubt, Development Compound includes Co-Developed Compounds.

Active Compound means a Compound that is shown in functional, in vitro testing using living human cells, and appropriately counter-screened or otherwise verified, to satisfy the threshold criteria set forth in the Research Plan for an effect as a UPR Modulator in the Indication specified by the Research Plan for the relevant Project.

The Licensor’s DRT™ platform utilizes functionally pertinent assays and disease relevant models to identify highly translatable therapies associated with the modulation of protein homeostasis pathways within the cell.

Field of Use
Licensee is intended to reduce the accumulation of unfolded proteins in the endoplasmic reticulum, which is observed in many diseases caused by an imbalance in the proteostasis network, including genetic, neurodegenerative and retinal degenerative diseases.

The proteostasis network (PN) comprises the intricately regulated interplay of signaling processes and molecular machines involved in the synthesis, folding, and clearance of the diverse spectrum of proteins comprising the folded, native proteome.

The collaboration will focus on one genetic disease, and further explore additional indications that can be affected through modulation of the UPR pathway. Stress induced by accumulation of unfolded proteins in the endoplasmic reticulum (ER) is observed in many diseases which are now recognized as protein conformational diseases, including genetic diseases, neurodegenerative diseases, and retinal degenerative diseases. Selective modulation of the UPR pathway in non-clinical investigations improved the stress response and restored function, suggesting that it can be beneficial as potential novel disease-modifying therapies for multiple diseases with high unmet medical needs.

A novel approach to drug discovery will enable rapid discovery and development of therapies for important unmet medical needs.  The collaboration will focus on one genetic disease, and further explore additional indications that can be affected through modulation of the UPR pathway. Stress induced by accumulation of unfolded proteins in the endoplasmic reticulum (ER) is observed in many diseases which are now recognized as protein conformational diseases, including genetic diseases, neurodegenerative diseases, and retinal degenerative diseases. Selective modulation of the UPR pathway in non-clinical investigations improved the stress response and restored function, suggesting that it can be beneficial as potential novel disease-modifying therapies for multiple diseases with high unmet medical needs.

Licensee is engaged in the research, development, production, marketing and sale of therapeutics and is interested in the development and commercialization of pharmaceutical products for treatment  through regulation of the proteostasis network with a focus on modulations of the human unfolded protein response (UPR).

IPSCIO Record ID: 286057

License Grant
Licensee desires to engage Licensor to create certain such cell lines, using the RAGE-VT technology, each of which expresses a specific cell surface or cellular protein of interest to Licensee, and to obtain license rights to use such cell lines for internal research, development and commercialization of pharmaceutical products.

Licensor shall create new Accepted Cell Lines based on RAGE-VT cell lines that Licensee proposes.

For the Research and Development License, and effective upon Licensors acceptance of a particular Accepted Cell Line, other than a Counterscreening Cell Line, Licensor grants to a non-exclusive, worldwide license, without the right to sublicense, under the Licensor Technology solely to use such Accepted Cell Line in the Field.

For the Evaluation License, as to each Collaboration Cell Line provided to Licensee by Licensor, Licensor grants a non-exclusive, worldwide license, without the right to sublicense, under the
Licensor Technology solely to conduct internal research evaluation of such Collaboration Cell Line.

For the Counterscreening License, and effective only upon Licensee s acceptance of a particular Accepted Cell Line that Licensee elected to be a Counterscreening Cell Line, Licensor grants to a non-exclusive, worldwide license, without the right to sublicense, under the Licensor Technology solely to use each such Counterscreening Cell Line for Counterscreening.

License Property
Licensor has technology relating to methods for activating gene or protein expression in cells, referred to by Licensor as the Random Activation of Gene Expression or RAGE technology, which includes the RAGE-VT technology useful for creating cell lines that express particular desired proteins.

Product shall mean any product containing a Candidate Compound, including any formulation, dosage form, packaged form or delivery means thereof.

RAGE Technology shall mean any and all intellectual property, whether or not patentable, that is owned or licensed by Licensor and relates to Licensor techniques for activating gene expression, which are referred to by Licensor collectively as Random Activation of Gene Expression or RAGE technology.

Licensor is a functional genomics and biopharmaceutical company engaged in the development, application and commercialization of novel gene expression tools and therapeutic products.

Field of Use
Field shall mean use of the Accepted Cell Lines by Licensee solely for Licensees internal discovery, research, development and/or commercialization of Products.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.